Stifel Reiterates Buy on Revolution Medicines, Raises Price Target to $215

Benzinga Newsdesk www.benzinga.com Positive 82.3%

Neg 0% Neu 0% Pos 82.3%

Stifel analyst Laura Prendergast reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $170 to $215.